BLI Banque de Luxembourg Investments Purchases New Holdings in Masimo Co. (NASDAQ:MASI)

BLI Banque de Luxembourg Investments purchased a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 101,200 shares of the medical equipment provider's stock, valued at approximately $17,067,000. BLI Banque de Luxembourg Investments owned 0.19% of Masimo at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its holdings in Masimo by 19.8% in the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after purchasing an additional 1,340,836 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Masimo by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after buying an additional 66,215 shares during the period. Capital Research Global Investors boosted its stake in shares of Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after buying an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Masimo by 119.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after acquiring an additional 943,001 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in Masimo by 8.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider's stock valued at $274,791,000 after acquiring an additional 135,888 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Piper Sandler reissued an "overweight" rating and set a $200.00 price objective (down previously from $215.00) on shares of Masimo in a report on Wednesday. Wells Fargo & Company lowered their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday. BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a report on Wednesday. Raymond James lowered their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $191.60.

Masimo Stock Up 2.0 %

Shares of Masimo stock traded up $3.06 on Friday, hitting $156.64. 952,687 shares of the company's stock traded hands, compared to its average volume of 660,211. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm's 50-day moving average is $162.18 and its 200 day moving average is $166.49. The stock has a market cap of $8.46 billion, a P/E ratio of 108.03 and a beta of 1.23. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. During the same period in the previous year, the business posted $0.77 EPS. The company's quarterly revenue was down 24.5% on a year-over-year basis. Equities analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.